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Background: Despite universal acceptance that smoking is harmful, a substantial number of adults continue to
smoke. The development of potential reduced exposure products (more recently termed modified risk tobacco
products) has been suggested as a way to reduce the risks of tobacco smoking. This trial is designed to investigate
whether changes in toxicant exposure after switching from a commercial to reduced toxicant prototype (RTP)
cigarette (7 mg International Organisation for Standardisation (ISO) tar yield) can be assessed by measurement of
biomarkers and other factors. The primary objective is to descriptively assess changes in selected biomarkers of
exposure (BoE) and biomarkers of biological effect (BoBE) within participants and within and between groups after
switching. Secondary objectives are to assess similarly changes in other biomarkers, quality of life, smoking
behaviours, physiological measures, mouth-level exposure to toxicants and sensory perception.
Methods/design: This trial will assess current smokers, ex-smokers and never-smokers in a single-centre single-
blind, controlled clinical trial with a forced-switching design and in-clinic (residential) and ambulatory (non-
residential) periods. Smokers will be aged 23–55 years (minimum legal smoking age plus 5 years) and non-smokers
28–55 years (minimum legal smoking age plus 5 years, plus minimum 5 years since last smoked). Smokers will be
allowed to smoke freely at all times. We will assess changes in selected BoE and BoBE and effective dose in urine
and blood after switching. Creatinine concentrations in serum, creatinine clearance in urine, cotinine concentration
in saliva, diaries and collection of spent cigarette filters will be used to assess compliance with the study protocol.
Mouth-level exposure to toxins will be assessed by filter analysis.
Discussion: Data from this study are expected to improve scientific understanding of the effects of RTP cigarettes
on BoE and BoBE, and give insights into study design for clinical assessment of potential MRTPs.
Trial registration: The study was registered in the Current Controlled Trials database under the reference
ISRCTN81286286.
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Despite universal acceptance that smoking is harmful, a
substantial number of adults continue to smoke. There
is likely to continue to be a substantial population of
smokers for the foreseeable future (1.6 billion smokers
worldwide is predicted in the year 2040) even with the
current tobacco control measures [1]. The concept of to-
bacco harm reduction, defined by the US Institute of
Medicine (IOM) as “decreasing total morbidity and mor-
tality, without completely eliminating tobacco and nico-
tine use” [2] is being considered by some regulators.
Development of potential reduced-exposure products
In the 2001 IOM report, Clearing the Smoke: the scien-
tific basis for tobacco harm reduction [2], the develop-
ment of potential reduced-exposure products (PREPs)
was suggested as a possible way to achieve tobacco harm
reduction. A PREP was defined as a product that results
in substantial reduction in exposure to one or more to-
bacco toxicants and that can reasonably be expected to
reduce the risk of developing one or more specific dis-
eases or other adverse health effects. The types of stud-
ies, including clinical trials, required to assess PREPs are
being considered [3]. In 2011 the IOM issued a further
report on the science needed to assess modified risk to-
bacco products (MRTPs) in response to the US FDA
who have released draft guidance on this.
In addition, a scientific committee that advises the
World Health Organization (WHO) has recommended
the mandated reduction of certain cigarette smoke toxi-
cants [4]. The potential for toxicant exposure and risk
reduction may be tested by the development and assess-
ment of reduced toxicant prototype (RTP) cigarettes. An
RTP has been developed with the use of novel technolo-
gies related to tobacco, filter, and cigarette format which
have been employed to reduce the yields of smoke toxi-
cants. The tobacco used in the RTP has been selected
for smoking acceptability and chemistry profiles (e.g.,
low in tobacco-specific nitrosamines and heavy metals)
and a proportion of the blend prepared with a new
process where tobacco is extracted with water and the
extract and fibres are treated separately to reduce certain
toxicant precursors before being recombined [5]. Add-
itionally, an inert non-tobacco sheet that contains a high
percentage of glycerol is also cut and mixed with the to-
bacco to dilute the concentrations of smoke toxicants
during smoking [6]. In order to reduce the yields of
some vapour phase toxicants, filters in the RTP incorpo-
rated a highly adsorbent form of carbon [7] and a select-
ive amine-functionalised resin [8].
Previous clinical study assessments
The tools to assess exposure to smoke toxicants were
examined in two previous clinical studies conducted inGermany and Canada using conventional cigarettes.
These studies aimed to assess whether the available
techniques could adequately assess human smoke expos-
ure by filter analysis and measurement of biomarkers of
exposure (BoE) [9-11]. These enable the exposure to-
bacco smoke toxicants or their metabolites to be mea-
sured in urine, or other biologic matrices. Both studies
showed a good correlation between exposure estimates
from the two methods, and, in the case of the German
study, the methods were senstive enough to detect
changes in smoke exposure following a switch to a
cigarette with a lower International Organization for
Standardization (ISO) tar yield [10].
Technologies used in the RTPs have previously been
shown to significantly reduce yields of a range of to-
bacco smoke toxicants by 10% to 95% compared with
typical commercial products with equivalent ISO tar
yields [12]. A clinical study of these RTPs, using a short-
term (6-week) switching design, determined smoke toxi-
cant exposure by measurement of various BoE in
current smokers after they switched from conventional
cigarettes to an RTP (ISRCTN 72157335) [13]. This
study showed that toxicant exposure was reduced after
switching to the RTP, although the prototypes required
further development to optimise the reductions and im-
prove acceptability to smokers.
However, reductions in smoke toxicant exposure alone
should not be assumed to result in a reduction in
smoking-related risk, and the studies noted above did
not investigate the potential for a reduction in risk of
smoking-related diseases or adverse biological effects.
Biomarkers of biological effect (BoBE) may serve as bio-
logical indicators of the body’s response to smoke expos-
ure. These include modifications in some parameters of
blood composition, alterations in activity of specific en-
zymes, the appearance of DNA adducts, localised in-
creases in messenger RNA and protein concentrations,
and the appearance of specific antibodies (autoanti-
bodies). BoBE may differ between smokers, non-smokers
and ex-smokers [3,14]. Ideally, smoking-related bio-
markers should be detectable early and have plausible
links to the early stages of smoking-related diseases.
While reductions in exposure to toxicants can be seen
within 2–4 weeks by measurement of BoE, it is antici-
pated that changes in biological effect measurable by
changes in BoBE, physiological or quality-of-life assess-
ments would take longer to manifest. Hatsukami et al.
[3] recommended that a series of clinical studies of both
short and intermediate duration be performed in the as-
sessment of PREPs/MRTPs. Previous studies (unpublished
data) indicate that a period of 6 months should be suffi-
cient to demonstrate the effects of reductions in exposure.
Three biomarkers have been identified that are sug-
gested in the literature to have the potential to enable
Table 1 Parameters in primary and secondary endpoints
Primary endpoints
Biomarkers of exposure
• Urine: Nicotine, cotinine, 3-hydroxycotinine and their glucuronide
conjugates, acrolein metabolite (3-HPMA), crotonaldehyde metabolite
(HMPMA), TSNA metabolites (total NNAL, total NNN, total NAT, total
NAB), 1,3-butadiene metabolite (MHBMA), acrylonitrile metabolite
(CEMA) and aromatic amines (4-aminobiphenyl, 3-aminobiphenyl,
o-toluidine, 2-aminonaphthalene), plus 9 PAH metabolites
(1-Hydroxynapthalene, 2-Hydroxynapthalene, 2-Hydroxyflourene,
1-, 2-, 3-, 4, and 9-Hydroxyphenanthrene, 1-Hydroxypyrene)
• Salivary cotinine
• Exhaled CO
Biomarkers of biological effect:
• Urine: F2-isoprostane (8-iso-PGF2 Type III and VI; for oxidative stress)
• Blood: white blood cells (for cardiovascular disease)
• Plasma: sICAM-1 (for cardiovascular disease)
Secondary endpoints
Biomarkers of exposure
• Urine: urine mutagenicity (Ames test)
Biomarkers of biological effect
• Urine: 8-OHdG, cis-thymidine glycol, 11-dehydrothromboxane B2
• Blood: gene expression, neutrophil count, monocyte count
• Erythrocytes: haemoglobin, superoxide dismutase activity,
glutathione peroxidase, glutathione reductase, catalase activity,
malondialdehyde
• Plasma or serum: IL-6, IL-8, ascorbic Acid, dehydroascorbic Acid,
total antioxidant capacity, hsCRP (males), fasting (12 h) lipid
profile (total cholesterol, LDL, HDL, Triglycerides), fibrinogen,
MCP-1, neutrophil elastase, MMP-1, MMP-9, TIMP-1, LTB4,
TNF-α, VEGF, oxLDL
Other features
• Filter analysis: MLE to nicotine and ‘tar’ (nicotine-free dry particulate
matter [NFDPM])
• Sensory testing questionnaire
• QoL questionnaire
• Smoking behaviours questionnaire
• Puffing and inhalation behaviour
• Pulmonary function test (FEV, FEV1, PEF)
• Biomarkers of Effective Dose (compliance monitoring)
• Haemoglobin adducts in blood: Acrylonitrile
(2-Cyanoethylvaline) and 4-ABP
3-HPMA, 3-Hydroxypropylmercapturic acid; HMPMA, 3-hydroxy-1-
methylpropylmercapturic acid; TSNA, Tobacco-specific nitrosamine;
NNAL, 4-(methylnitrosamino)-1-(2-pyridyl)-1-butanol; NNN, N-nitrosonornicotine;
NAT, N-nitrosoanatabine; NAB, N-nitrosoanabasine; MHBMA,
monohydroxybutenylmercapturic acid; CEMA, 2-cyanoethylmercapturic acid; PAH,
Polyaromatic hydrocarbons; CO, Carbon monoxide; PGF2, prostaglandin F2; sICAM-1,
soluble intercellular adhesion molecule; 8-OHdG, 8-oxo-2′-deoxyguanosine; IL-6,
Interleukin 6; IL-8, Interleukin 8; hsCRO, high-sensitivity C-reactive protein; LDL, Low-
density lipoprotein; HDL, High-density lipoprotein; MCP-1, Monocyte chemotactic
protein-1; MMP-1, Matrix metalloproteinase-1; MMP-9, Matrix metalloproteinase-9;
TIMP-1, Tissue inhibitor of metalloproteinase 1; LTB4, Leukotriene B4; TNF-α, Tumour
necrosis factor-alpha; VEGF, Vascular endothelial growth factor; oxLDL, oxidised low-
density lipoprotein; MLE, mouth level exposure; NFDPM, nicotine free dry particulate
matter; QoL, Quality of life; FEV, Forced expiratory volume; FEV1, Forced expiratory
volume in 1 second; PEF, Peak expiratory flow; 4-ABP, 4-aminobiphenyl.
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markers, termed biomarkers of effective dose (BoED),
are DNA and protein adducts of identified smoke toxi-
cants that have relatively long half-lives (50–55 days). In-
terrogation of these data, therefore, could be useful for
the monitoring of behaviour and compliance over ex-
tended periods of time.
Other elements to consider in clinical studies are
mouth-level exposure (MLE) to tar and nicotine [13]
and whether changes in exposure affect any basic
physiological features or quality of life. Sensory features
are also important to assess, particularly in relation to
compliance to protocol in a switching study.
Study hypothesis and objectives
The study is intended to test the hypothesis that
switching of smokers from conventional cigarettes to
RTP cigarettes will result in measurable reductions in
exposure to toxicant and lead to beneficial changes in
biological effects, as shown by assessment of biomarkers.
The primary objective of this study is to descriptively
assess changes in selected BoE and BoBE (Table 1),
within participants and within and between groups, after
a forced switch from a commercial control cigarette to
an RTP cigarette of equivalent ISO tar yield. Secondary
objectives are to descriptively assess changes within par-
ticipants and within and between groups in further BoE,
BoBE and BoED, quality of life, smoking behaviours,
physiological measures, MLE and sensory perception,
and to descriptively assess changes in the primary and
secondary end points together after switching, in com-
parison with values for ex-smokers and never-smokers
(Table 1). Data from this study are expected to improve
the scientific understanding of tobacco products.
Methods/design
Study design
This study will be a single-centre, single-blind, con-
trolled clinical trial with a forced-switching design that
will be conducted in Hamburg, Germany. The study will
be partly clinic-based (residential) and partly ambula-
tory (non-residential, including brief visits to the clinic).
This study will be conducted in compliance with the
ethical principles of the Declaration of Helsinki, Good
Clinical Practice [17,18] and German law. When the
Principal Investigator signs the protocol, he or she will
be agreeing to adhere to the instructions and proce-
dures described in it.
The Principal Investigator or designated investigators
will ensure that participants are given full and adequate
oral and written information in non-technical terms
about the nature, purpose, potential risks and possible
benefits of study participation. Participants will be given
time to consider all the information, the opportunity to
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informed consent forms that summarise the discussion
before participating in any procedures related to the study.
The protocol and the informed consent forms have been
approved by the ethics committee of the Ärztekammer
Hamburg, Hamburg, Germany (Processing Number
PV3824).
The study has a forced-switching design to enable data
to be obtained about changes in exposure to tobacco
smoke toxicants and related biological effects. The ef-
fects of RTP cigarettes will thus be evaluated within in-
dividuals (switching smokers serve as their own control)
and between individuals (switching versus non-switching
smokers). The ex-smoker and never-smoker control
groups will provide background levels of BoE arising
from environmental sources. They will also provide ref-
erence levels of BoBE that would be expected in people
who have given up smoking for at least 5 years or who
have never smoked. The inclusion of multiple types of
non-smoker control groups is anticipated to improve the
interpretation of the data generated in this study.
Financial compensation for the inconvenience to and ef-
fort of participants will be offered as part of the study, but
the sponsor does not wish this approach to incentivise
participants to smoke. Stipends will, therefore, be calcu-
lated independently by the clinic according to the usual
rates for this type of clinical study and will be approved by
the ethics committee of the Ärztekammer Hamburg.
Study participants
Identification of study participants
Participants will be recruited into the study through ad-
vertisements on the clinic’s own website and local adver-
tising that will not refer to the characteristics of the
study products. All study participants (smokers and
non-smokers) will be sourced from the Hamburg area
from the same communities. Adult, healthy participants
of either sex and of any ethnic origin will be enrolled.
The planned ratio of male to female participants within
each subgroup of the smoking groups is between 3:2 and
2:3, that is, an attempt will be made to enrol approxi-
mately equivalent numbers of male and female subjects
into each subgroup, within these tolerances.
Inclusion criteria
The suitability of participants who give informed con-
sent will be assessed according to the inclusion criteria
within 28 days before entering the study and verified
upon arrival at the clinic for the first in-clinic evaluation
period. The universal inclusion criteria are weight of at
least 52 kg (men) or 45 kg (women) and body-mass
index within the normal range; no relevant clinically ab-
normal findings on physical examination, electrocardiog-
raphy, clinical laboratory testing or lung function tests,or in the medical history, as judged by the investigators;
the ability to communicate well with the investigators
and understand and comply with the requirements of
the study; willingness to refrain from consuming alcohol
within 72 h before the first day of each in-clinic evalu-
ation (an alcohol breath test result of up to 0.05% alco-
hol at the start of a visit might be tolerated, at the
discretion of the investigators); willingness to refrain
from consuming and avoid being in the presence of the
cooking of grilled, fried or barbequed food for 48 h be-
fore the first day of each in-clinic evaluation; not being
pregnant or breastfeeding and using a reliable method of
contraception (e.g., abstinence or barrier methods with
spermicide from at least one menstrual cycle before the
first day of the study until at least one menstrual cycle
after the last in-clinic evaluation, surgical sterilsation of
self or partner ≥6 months before the study, an intrauter-
ine device in place or hormonal contraceptives started
≥3 months before the study until at least one menstrual
cycle after the last in-clinic evaluation), or being post-
menopausal with amenorrhea for at least 2 years.
Additional inclusion criteria for the smoking groups
are age 23–55 years; being a regular current smoker of a
brand of cigarettes with an ISO tar yield of 6–8 mg and
a blend style and mechanics similar to brands sold in
Germany; having smoked the same brand for a mini-
mum of 6 months and any brand for at least 5 years be-
fore screening; smoking of 10–30 cigarettes per day;
willingness to switch to an RTP cigarette and to smoke
only products provided during the study; and having a
urinary cotinine level of >100 ng/mL.
Additional inclusion criteria for the ex-smoking group
are age 28–55 years; not having smoked for at least
5 years but having been a regular smoker of 10–30 ciga-
rettes per day for at least 5 years previously; having a
urinary cotinine level of <30 ng/mL (inclusive of levels 0
and 1 on the NicAlert™ test, Palico, Rotkreuz, Switzerland)
at screening and <100 ng/mL (inclusive of levels 0–2 on
the NicAlert™ test) during the study. Additional inclusion
criteria for the never-smoking group are age 28–55 years;
never having smoked more than 100 cigarettes during his
or her lifetime, and none in the previous 5 years; and
having a urinary cotinine level of <30 ng/mL (inclusive
of levels 0 and 1 on the NicAlert™ test) at Screening
and <100 ng/mL (inclusive of levels 0–2 on the NicAlert™
test) during the study.
Documented exceptions to the inclusion criteria may
be permitted at the discretion of the investigators, in
agreement with the sponsor, providing risks to partici-
pants would not be increased and the realisation of the
scientific objectives of the study would not be hindered.
Occasional use of paracetamol (up to 4 g per day) might
be permitted at the discretion of investigators. Should the
need arise to take any other medications, investigators
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the need should be reported before medication is started.
All medication administered during the study will be
documented, either by the participant during ambulatory
periods or by investigators during in-clinic evaluations. In
the case of other medical complaints, participants should
inform the physician in charge of the study. A physician
will be on duty during the entire course of the study,
although participants will be referred to their personal
physician whenever appropriate (e.g., for the treatment of
chronic medical conditions).Exclusion criteria
Exclusion criteria may be applied at screening or at any
time during the study. The universal exclusion criteria are
clinically relevant gastrointestinal, renal, hepatic, neuro-
logical, haematological, endocrine, oncological, urological,
pulmonary, immunological, psychiatric or cardiovascular
disorders or any other conditions that, in the opinion of
the investigators, would jeopardise the safety of the par-
ticipant or affect the validity of the study results; abnormal
findings on physical examination, in the medical history,
or in clinical laboratory results deemed clinically relevant
by investigators; participation in a previous clinical trial
within 30 days before entering the study; donation or loss
of at least 400 mL blood within 90 days before entering
the study; donation of plasma within 7 days before enter-
ing the study; acute illness (e.g., upper-respiratory-tract in-
fection, viral infection etc.) requiring treatment within
4 weeks before entering the study; regular use of any
nicotine or tobacco products other than commercially
manufactured filter cigarettes; self-reported non-inhaling
smoking behaviour (drawing of smoke into the mouth and
throat without inhaling); observed as being non-inhalers
by the clinic staff at first in-clinic evaluation; history of
drug or alcohol abuse within 24 months before screening;
positive alcohol breath test and/or urine screen for illicit
drugs; positive result for HIV or hepatitis; use of prescrip-
tion or over-the-counter bronchodilator medications (e.g.,
inhaled or oral β-agonists) to treat chronic conditions
within 12 months before entering the study; use of any
medications that interfere with the cyclo-oxygenase path-
way (e.g., aspirin or ibuprofen) within 14 days before
entering the study; use of any prescribed systemic medica-
tion within 14 days before entering the study (except for
hormonal contraceptives and hormone-replacement ther-
apy); use of any drugs or substances (except tobacco)
known to be strong inducers or inhibitors of CYP (cyto-
chrome P450) enzymes within 28 days before entering the
study (Table 2); strenuous physical activity (exceeding the
participant’s normal activity levels) within 7 days before
screening or in-clinic evaluations; pregnancy; and employ-
ment or being first-degree relatives to employees of thetobacco, journalism (television and radio), public relations,
market research or advertising industries or the clinic.
For the smoking groups an additional exclusion criter-
ion at screening is planning to quit smoking in the next
12 months (although cessation counselling will be avail-
able to smoking participants during and at the end of
the study). For the non-smoking groups, additional ex-
clusion criteria are smoking at any time during the study
and regular exposure to second-hand smoke (e.g.,
through living in a household or working with smokers).Withdrawal from the study
Participants will be allowed to withdraw from the study
at any time. If they do so, they will receive a pro rata sti-
pend. Investigators may at any time withdraw a partici-
pant from the study if they deem this action to be in his
or her best interest or that of other participants. The
end-of-study examination should be undertaken when a
participant leaves the study, if he or she agrees, and rea-
sons for withdrawal should be recorded. If patients can-
not be assessed because he or she cannot be contacted
after non-attendance of a scheduled event, they will be
reported as lost to follow-up.
Participants will be informed of the importance of
conforming to all requirements of the protocol, but vio-
lations might not result in removal from the study, as
the sponsor realises that 100% compliance for every par-
ticipant over the 6 month period of the study is unlikely.
Honesty about protocol violations will, therefore, be en-
couraged. Participants will be asked to record and report
at each clinic visit during ambulatory periods instances
when they have not adhered to the protocol, or at check
in for in-clinic evaluations. Investigators will decide
whether non-compliant participants may remain in the
study. Although withdrawals or dropouts are not
expected to be replaced, the Sponsor will consider re-
placing participants to maintain the power of the study.Study groups
Participants will be assigned to study groups primarily
on the basis of whether they are smokers, ex-smokers or
never smokers. The demographics for each group will be
matched as far as possible (accepting the constraints of
the minimum age difference between smokers and non-
smokers) i.e. participants’ sex and age will also be taken
into account. The assignment of control cigarettes or
RTP cigarettes will be kept within cohorts, i.e., all partic-
ipants in a smoker subgroup will be switched to the
same study product at the same time to meet the restric-
tions posed by the predetermined schedule for the con-
duct of the study. For practical reasons, including clinic
capacity and sample collection, the smoker and non-
smoker groups will be further split into two subgroups
Table 2 Strong inducers or inhibitors of CYP (cytochrome
P450) enzymes [19]
INHIBITORS
1A2 2B6 2C8 2C19
Cimetidine Thiotepa Gemfibrozil Fluoxetine






2C9 2D6 2E1 3A4,5,7


















1A2 2B6 2C8 2C19
N/A Phenobarbital N/A N/A
Phenytoin
Rifampin
2C9 2D6 2E1 3A4,5,7








(Adapted with permission from Version 5.0 (http://medicine.iupui.edu/
clinpharm/ddis/table.aspx)).
1A2, 2B6 etc = CYP enzyme subtypes.
Shepperd et al. BMC Public Health 2013, 13:690 Page 6 of 16
http://www.biomedcentral.com/1471-2458/13/690(Figure 1). Therefore, to ensure enough participants are
recruited to all subgroups, that subject availability will
be assured and groups will be well matched for age and
gender, we have accepted that full randomisation is not
possible. Smokers will be recruited and subgroups filled
according to order of screening, age, gender and avail-
ability at the study start time. Non-smokers will be
recruited on the basis of the same criteria in an attempt
to match the control group well with the smoker-group
demographics.
The study events will be scheduled to avoid as far as
possible overlap of subgroups for in-clinic evaluations;
non-smoking subgroups will never be resident in the
clinic at the same time as any smoking subgroup.
Investigational products
All study cigarettes will be provided by the sponsor free
of charge (Table 3). To achieve blinding, unbranded cig-
arettes and packs will be manufactured specifically for
the study. All packaging will include the mandatory
health warnings, details of yields and tax stamps. The
control cigarettes will match the specifications of the
commercial cigarettes supplied before switching, except
for a visual but cosmetic difference (i.e., plain white tip-
ping on the control versus cork patterned tipping on the
commercial cigarette; Table 3). This will allow RTP and
control smoker cohorts to see a noticeable change to
their cigarettes without being able to determine which
product they are receiving. The different cigarette prod-
ucts will be identifiable to the clinic pharmacy staff and
investigators by study identification codes (Table 3) that
will be printed on the packaging and on the individual
cigarettes. The cigarette products will be stored in a
locked, limited-access area under controlled temperature
and humidity conditions.
Study procedures at each visit
Screening
Participants who have signed informed consent forms
will be eligible for screening. Medical history, smoking
history and demographic data (e.g., sex, age, ethnic ori-
gin, etc.) will be recorded. Each participant will be re-
quired to provide proof of age with a form of
identification accepted by MOMENTUM Pharma Ser-
vices (i.e., national identity card or work or residence
permit).
Participants will undergo the following assessments:
physical examination, including measurement of height,
weight, blood pressure, pulse rate and temperature; 12-
lead electrocardiography; pulmonary function testing;
clinical laboratory tests; testing for infection with hepa-
titis virus B and C and HIV; urine pregnancy test for
women; urine drug screening; and alcohol breath test.
Urine will be taken for cotinine testing to confirm
NDay 1 first day of study, smokers start on supplied control cigarette
Clinical Confinement for 24h urine, 24h butt, blood sample collections, etc.
Ambulatory visits for cigarette re supply and compliance monitoring
Switch from control_v1 to RTP or control_v2 cigarette
7 8 9 10
1 2 3 Week number
Ex Smokers 30
Screening 1 2 3 4 5 6
8 9
23 2411 12 13 14
Never Smokers 30
Screening 1 2 3 4 5
19 20 21 2215 16 17 18
2219 20 2114 23 24
7mg Control A 35
Screening 1 2 3 4
1815 16 1710 11 12 136 7
2721 2219 2013 14 15 16
7mg Control B 35
Screening 1 2 3 4
25 2623 2417 189 10 11 125 6 7 8
2721 2219 2013 14 15 16
1 2 3 4
25 2623 2417 189 10 11 125 6 7 8
2721 2219 2013 14 15 16
7mg Test B 35
Screening 1 2 3 4
25 2623 2417 189 10 11 125 6 7 8
7mg Test A 35
Screening
13 14 15 169 10 11 125 6 7 8 25 2623 2417 18 2721 2219 20
Never Smokers 30




Screening 1 2 3
2420 21 22 2313 14 15 16 17 198
4 5
18




7 2420 21 22 231914 15 16 17
Figure 1 Study design and scheduled events.
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general observations and questioning may be added by
the investigators.Ambulatory visits
Participants in the smoking groups will visit the clinic
on the first day of the first ambulatory period (Figure 1).
Smoking subjects will be asked to confirm the ISO tar
yield of their usual brand and smoking status of all sub-
jects will be verified by a urine cotinine test. Participants
will be given a diet sheet to which they will be asked to ad-
here during specified times in ambulatory periods (i.e. 48 h
before each in-clinic evaluation). Participants will be sup-
plied with cigarettes according to their assigned product
(Table 3) and daily consumption rate, plus two packs, and
asked to smoke only the supplied brand until their next
visit. Smokers will be allowed to smoke ad libitum, rather
than according to a pre-specified quantity or timetable.
Each participant will be trained how to use an elec-
tronic diary in which he or she will be asked to docu-
ment cigarette consumption, diet, exercise, medications
and any other health-related issues on every ambulatoryTable 3 Investigational products
Study period Control group
Days 1–14 Lucky Strike Silver (ID W861) with mono CA filter, cork
tipping and commercial tobacco blend
Yields using ISO methodology: 7 mg tar, 0.6 mg nicotine
8 mg CO
Days 15–183 Lucky Strike Silver (ID H285) with mono CA filter, white
tipping and commercial tobacco blend
Yields using ISO methodology: 7 mg tar, 0.6 mg nicotine
8 mg CO
ID, study identification code, CA, cellulose acetate, CR20, amine-functionalised resin
cigarette, ISO, International Organisation for Standardisation. ato be confirmed.day. Participants will be required to bring the diary to
every clinic visit.
Further ambulatory clinic visits will be made on days
31, 62, 95, 124, 144 and 165 (Figure 1). During these
visits, diary entries will be checked, any protocol viola-
tions (e.g. consumption of cigarettes that were not sup-
plied by the sponsor, significant health-related events or
intake of excluded medications) will be assessed and de-
cisions made about further participation in the study.
Urine samples will be taken and tested for cotinine.
Cigarette butts will be collected for analysis and the
numbers of butts will be compared with diary entries
and recorded. Participants will be supplied with further
study cigarettes (normal daily consumption x number of
days, plus two packs) and reminded to smoke only those
until their next visit. They will also receive fresh tins to
collect cigarette butts. The clinic staff will record infor-
mation on hard copy case report forms during visits and
will later be transcribed into an electronic system.
In-clinic evaluations
The first in-clinic evaluation for the smoking groups will
be on days 12–15 (Figure 1, Table 4). Participants willTest group
-print Lucky Strike Silver (ID W861) with mono CA filter, cork-print
tipping and commercial tobacco blend
, Yields using ISO methodology: 7 mg tar, 0.6 mg nicotine,
8 mg CO
RTP (ID G429) with triple CA/CR20/charcoal filtera, white
tipping and study tobacco blend (20% non-tobacco sheet,
50% treated tobacco and 30% commercial blend).
, Yields using ISO methodology: 7 mg tar, 0.7 mg nicotine,
8 mg COa
filter additive, CO, carbon monoxide, RTP, reduced-toxicant prototype
Table 4 Schedule for first in-clinic evaluation of smokers
Day and suggested times Sampling Procedure
12
1700 h (check in) Blood, urine Measure BP, PR, RR and temperature; abbreviated physical examination and medical
history; illicit drug, alcohol and cotinine testing; pregnancy testing; collection of diary
and cigarette butts; dinner
1900 h None Start first 24 h urine collection, monitoring of cigarette consumption and collection
of filters
2100 h None Snack
13
0700 h Blood Measure BP, PR, RR and temperature; blood collection for creatinine in serum,
biomarkers and gene expression
0800 h None Breakfast
To be scheduled None Assess smoking behavioura
1000 h None Administer sensory, quality-of-life and diet and lifestyle questionnairesb
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Saliva cotinine testing; dinner
1900 h None End first and start second 24 h urine collection, monitoring of cigarette consumption
and collection of filters
2100 h None Snack
14
0700 h Blood Measure BP, PR, RR and temperature; blood collection for creatinine in serum,
biomarkers and gene expression
0800 h None Breakfast
To be scheduled None Assess smoking behavioura
1100 h None Pulmonary-function test
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Saliva cotinine testing; dinner
1900 h None End second 24 h urine collection, monitoring of cigarette consumption and
collection of filters; switch to next assigned product
2100 h None Snack
15
0700 h None Measure BP, PR, RR and temperature
0800 h None Breakfast
1000 h None Administer sensory questionnaire
1200 h None Lunch
1700 h None Dinner
1900 h None End filter collection; dispense interventional products and cigarette butt collection
tins for use at home, remind participants of instructions for diet and completion
of diaries
BP, blood pressure, PR, pulse rate, RR, respiratory rate CO, carbon monoxide, aTo be performed by sponsor. bMay be done on day 14.
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http://www.biomedcentral.com/1471-2458/13/690check in on the evening of the first day and remain in
the clinic until the evening of the final day. Participants
will be instructed at check in on how to request ciga-
rettes and return the butts within the clinic. During this
and all other in-clinic evaluations, sufficient amounts of
cigarettes for each smoker per day, transferred in
participant-specific containers, will be made available bythe site pharmacy and the clinic pharmacy staff and in-
vestigators will keep dispensing records. All cigarettes
will be smoked only in a designated smoking area with
appropriate ventilation.
On the evening of day 14, after completion of the 24 h
urine collection, smokers will be switched to their next
assigned product (control or RTP). Upon discharge on
Shepperd et al. BMC Public Health 2013, 13:690 Page 9 of 16
http://www.biomedcentral.com/1471-2458/13/690the morning of Day 15, participants will be given suffi-
cient supplies of the new product and butt collection
tins to last until the next visit. After switching, smokers
will undergo four more in-clinic evaluations on days 45–
46, 76–77, 108–109 and 181–183 (Tables 5 and 6).
In previous smoking studies, most smokers (>90%)
have increased the number of cigarettes they smoke on
the last day of the study, typically by two to three ciga-
rettes per day, which can adversely affect statistical out-
comes. This increase is thought to be due to the
impending end of the supply of free cigarettes. To miti-
gate this effect, at discharge from the last in-clinic evalu-
ation, all smoking participants will be supplied with
7 days’ worth of their baseline product and asked to rec-
ord daily consumption over the next 7 days. Participants
will be contacted by telephone on the 7th day to obtain
data on consumption.
In previous smoking studies based at the Hamburg
clinic, it has been an absolute requirement of the ethics
committee that smoking cessation counselling is pro-
vided to smoking subjects during the study. Therefore,
several optional smoking-cessation workshops will be
held during the study, for groups of 20–25 participants
and led by a psychologist experienced in smoking cessa-
tion. The format will be a mix of lectures (including
presentations, demonstrations and case studies), self-
assessment (tests and questionnaires) and team and
small-group work. The main aims of workshops will be
to improve the knowledge of the participants about
smoking cessation options, help participants to makeTable 5 Schedules for second, third and fourth in-clinic evalu
Days and suggested times Sampling Procedure
45, 76, 108




1900 h None Start 24 h urin
of filters
2100 h None Snack
46, 77, 109
0700 h Blood Measure BP, P
and gene exp
0800 h None Breakfast
1000 h None Administer sen
questionnaires
1200 h None Lunch
1500 h None Measure exhal
1700 h Saliva Cotinine testin
1900 h None End 24 h urine
dispense inter
remind partici
BP, blood pressure, PR, pulse rate, RR, respiratory rate, CO, carbon monoxide, aOn drealistic self-assessments regarding smoking cessation,
increase participants’ motivation to quit or reduce smok-
ing and develop individual plans for quitting or reducing
smoking. Each workshop will take 60–90 min. Addition-
ally, the Smoke-Free Programme of the Munich Institut
für Gesundheitsförderung will be offered to all smoking
subjects who wish to participate. The approach involves
three meetings of 180 min and two telephone consulta-
tions. Following a preparatory phase, a day to quit smok-
ing will be decided for all attendees. Strategies to handle
irritation and critical situations and for behaviour con-
trol will be provided and alternative behaviours devel-
oped. In the final phase, the emphasis will be on
prevention of relapse. Participants will be reminded of
the dangers of smoking before enrolment, will be free to
voluntarily quit smoking and withdraw from the study at
any time and may still access the smoking-cessation
workshops.
Ex-smokers and never smokers will be assessed in
three in-clinic evaluations, on days 1–3, 78–80 and 162–
164 (Figure 1, Table 7). As for the smoking groups, they
will arrive in the evening of the first day and will remain
in the clinic until the evening of final day of each visit.
Assessments
Cigarette consumption
Participants will be required to document cigarette con-
sumption during ambulatory periods in diaries. In
addition, on selected days, participants will be asked to
collect the butts of smoked cigarettes in speciallyations of smokers
R, RR and temperature; abbreviated physical examination and
y; illicit drug, alcohol and cotinine testing; pregnancy testing;
ary and cigarette butts; clinical laboratory tests; electrocardiography;
tests; dinner
e collection, monitoring of cigarette consumption and collection
R, RR and temperature; measure creatinine in serum; biomarkers
ression




collection, monitoring of cigarette consumption and collection of filters;
ventional products and cigarette butt collection tins for use at home,
pants of instructions for diet and completion of diaries
ay 108–109 visit only; may be conducted on either day.
Table 6 Schedule for final in-clinic evaluation of smokers
Day and suggested times Sampling Procedure
181
1700 h (check in) Blood, urine Measure BP, PR, RR and temperature; abbreviated physical examination and medical
history; illicit drug, alcohol and cotinine testing; pregnancy testing; collection of diary
and cigarette butts; dinner
1900 h None Start first 24 h urine collection, monitoring of cigarette consumption and collection
of filters
2100 h None Snack
182
0700 h Blood Measure BP, PR, RR and temperature; measure creatinine in serum; biomarkers and
gene expression
0800 h None Breakfast
To be scheduled None Assess smoking behavioura
1000 h None Administer sensory, quality-of-life and diet and lifestyle questionnaires†
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Cotinine testing; dinner
1900 h None End first and start second 24 h urine collection, monitoring of cigarette consumption
and collection of filters
2100 h None Snack
183
Anytime (check out) None Measure BP, PR, RR and temperature; physical examination; electrocardiography
0700 h Blood Measure creatinine in serum; biomarkers
0800 h None Breakfast
To be scheduled None Assess smoking behavioura
1100 h None Pulmonary-function test
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Cotinine testing; dinner
1900 h None End second 24 h urine collection, monitoring of cigarette consumption and collection
of filters; dispense adequate commercial products of normal ISO tar yield for 7
post-study days
BP, blood pressure, PR, pulse rate, RR, respiratory rate, CO, carbon monoxide, aTo be performed by sponsor. †May be done on day 183.
Shepperd et al. BMC Public Health 2013, 13:690 Page 10 of 16
http://www.biomedcentral.com/1471-2458/13/690supplied tins and bring them to the next clinic visit.
Butts will be counted to confirm the accuracy of diary
entries on consumption. Participants will also be re-
quired to present any un-smoked cigarettes and the
empty packets from smoked cigarettes. During in-clinic
evaluations smokers’ cigarette consumption will be mon-
itored by the clinic staff. Cigarettes will be issued to par-
ticipants by staff one at a time, upon request, as they
enter the designated smoking area and the butts of all
smoked cigarettes will be collected by staff when
smokers leave the smoking area.
Clinical and bioanalytical laboratory tests
The tests shown in Table 8 will be performed at screen-
ing for smokers and non-smokers. All tests, except for
the HIV and hepatitis serology, will also be performedduring the smokers’ in-clinic evaluation on days 108–
109 and at the end of the study.Urine tests Before the start of each 24 h urine collection
period during in-clinic evaluations (Tables 5, 6, 7), each
participant will be required to empty his or her bladder.
Following this, each void will be collected in separate la-
belled brown plastic bottles and stored at 2-8°C. Col-
lected urine will be pooled and stored at 2–8°C, labelled
with the day on which collection ended. The total vol-
ume of urine collected over each 24 h period will be cal-
culated from weight and specific gravity. After thorough
mixing, samples will be transferred to labelled tubes and
stored at −18 to −25°C. The details of biomarker assess-
ments are shown in Table 9.
Table 7 Schedule for in-clinic evaluations of ex-smoker and never-smoker groups
Day and suggested times Sampling Procedure
1, 78, 162
1700 h (check in) Blood, urine Measure BP, PR, RR and temperature; abbreviated physical examination and
medical history; illicit drug, alcohol and cotinine testing; pregnancy testing; dinner
1900 h None Start first 24 h urine collection
2100 h None Snack
2, 79, 163
0700 h Blood Measure BP, PR, RR and temperature; measure creatinine in serum; biomarkers
and gene expressiona
0800 h None Breakfast
1000 h None Administer quality of life and diet and lifestyle questionnairesb
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Cotinine testing; dinner
1900 h None End first and start second 24 h urine collection
2100 h None Snack
3, 80, 164
0700 h Blood Measure creatinine in serum; biomarkers
0800 h None Breakfast
1000 h None Administer quality of life and
1100 h None Pulmonary-function test§
1200 h None Lunch
1500 h None Measure exhaled CO
1700 h Saliva Cotinine testing; dinner
1900 h None End second 24 h urine collection
164 (check out)
Any time Blood, urine Measure BP, PR, RR and temperature; physical examination;
electrocardiography; clinical laboratory tests
aNot on day 79. bNot during visit on days 1–3; may be performed on day 79 or 80 and on day 163 or 164.
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http://www.biomedcentral.com/1471-2458/13/690Three haemoglobin adducts of identified smoke toxi-
cants will be measured as BoED. Additionally, BoE that
can yield information on short-term compliance, for ex-
ample assessment of the ratio of a BoE for a smoke toxi-
cant that does not change significantly between the
products (such as nicotine) to a smoke toxicant that
does significantly change (such as acrolein or NNK), will
also be measured.
To ensure that every urine collection is complete for
all participants, 24 h creatinine clearance will be calcu-
lated during the 24 h urine collection period. Creatinine
clearance values will be verified by investigators, taking
into account urine volumes and serum creatinine re-
sults. Values outside the normal clinical range (1.33–
1.92 mL/s/m2) may be classified as acceptable, since
values have been reported to vary greatly between indi-
viduals and a substantial proportion are likely not to fall
within this range.
Samples available for long-term storage after the study
will be kept at the sponsor’s biological sample archive.Saliva tests Saliva samples will be collected with
Salivettes without citric acid (Sarstedt, Nuembrecht,
Germany) at specified times during in-clinic evaluations
(Tables 4, 5, 6, 7). The cellulose dams will be gently
moved around the mouth for 2 min and light chewing
will be allowed. The loaded dams will then be returned
to the original tubes before centrifugation at 1000 g for
2–5 min at room temperature. The clear saliva sample
will be stored at −20°C until assay. Cotinine concentra-
tions will be measured with a validated assay (Celerion,
Lincoln, NE, USA).
Blood tests Blood samples will be collected in blood-
collection tubes. The blood volumes required for bio-
marker analyses and the biomarkers to be assessed are de-
tailed in Table 10. Global gene expression profiles will be
analysed with GeneChip expression arrays (Affymetrix,
Santa Clara, CA, USA; [20]), which are accepted as an in-
dustry standard [21] and have been used successfully for
clinical studies [22]. Any unused split samples will be








● Mean corpuscular volume
● Mean corpuscular haemoglobin
● Mean corpuscular haemoglobin concentration
Clinical chemistry




























● Alcohol breath testb
● Urine cotinineb
● HIV
● Hepatitis surface antigen
● Hepatitis C virus
● Urine drug screeningb











● Urine pregnancy testb
All tests, except the additional tests, will also be performed during the
smokers’ day 108–109 in-clinic evaluations and at the end of the study.
aTo be repeated in each 24 h in-clinic evaluation for all participants.
bTo be repeated at all in-clinic evaluation visits for smokers and non-smokers.
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the end of the study, at least until publication of the study
results, to allow for any necessary repeat analyses.Exhaled carbon dioxide
Expired carbon monoxide (CO) levels will be measured
with the EC50 Micro III Smokerlizer CO meter
(Bedfont, Maidstone, UK), or similar device at specified
times (Tables 4, 5, 6, 7).Table 9 Urinary biomarkers
Biomarker Number and volume of aliquots
4-Aminobiphenyl, 3-Aminobiphenyl, 2 aliquots of 12 mL each
o-Toluidine, 2-Aminonaphthalene
OH-PAHs suite 2 aliquots of 12 mL each
Nicotine + 5 2 aliquots of 6 mL each
3-HPMA, HMPMA, CEMA 2 aliquots of 3 mL each
MHBMA 2 aliquots of 3 mL each
Total NNAL, NNN, NAB and NAT 2 aliquots of 10 mL each
F2-isoprostane (8-iso-PGF2 Type III) 2 aliquots of 6 mL each
F2-isoprostane (8-iso-PGF2 Type VI) 2 aliquots of 6 mL each
11-dehydrothromboxane B2 2 aliquots of 3 mL each
Urine mutagenicity 1 aliquots of 300 mL each
8-OHdG 2 aliquots of 1.5 mL each
Cis-thymidine glycol 2 aliquots of 1.5 mL each
OH-PAH, phenolic polycyclic aromatic hydrocarbons.3-HPMA,
3-Hydroxypropylmercapturic acid.
HMPMA, 3-hydroxy-1-methylpropylmercapturic acid. CEMA,
2-cyanoethylmercapturic acid.
MHBMA, monohydroxy-3-butenylmercapturic acid. NNAL,
4-(methylnitrosamino-1-(3-pyridyl)-1-butanol.
NNN, N-nitrosonornicotine. NAB, N-nitrosoanabasine. NAT, N-nitrosoanatabine.
8-OhdG, 8-Oxo-2′-deoxyguanosine.




2-cyanoethylvaline 2 × 4.9 mL EDTA Erythrocytes
4-ABP Hb adduct 2 × 4.9 mL EDTA Erythrocytes
IL-6, IL-8, MCP-1, TNF-a, VEGF, MMP-1, MMP-9, TIMP-1, ox LDL,
superoxide dismutase activity, glutathione peroxidase activity,
glutathione reductase activity, catalase activity, Hb (lysate)
1 × 9 mL EDTA Plasma, lysate
Total antioxidant capacity 1 × 4.7 mL serum Serum
Ascorbic acid, dehydroascorbic acid 1 × 7.5 mL EDTA Plasma
Neutrophil elastase, fibrinogen 1 × 5 mL citrate Plasma
Hb (lysate), malondialdehyde 1 × 7.5 mL li-heparin Lysate, cell pellet
sICAM-1 1 × 4 mL EDTA Plasma
hsCRP (males) 1 × 8.5 mL serum Serum
Lipid Profile 1 × 8.5 mL serum Serum
LTB4 1 × 4 mL li-heparin Plasma
White blood cells, neutrophils, monocytes, haemoglobin 1 × 2.7 mL EDTA Plasma
Gene expression 2.5 mL × 2 Paxgene Plasma
4-ABP Hb adduct, 4-aminobiphenyl haemoglobin adduct. IL-6, interleukin-6. IL-8, interleukin-8.
MCP-1, Monocyte Chemoattractant Protein 1. TNF-a, Tumor necrosis factor alpha.
VEGF, Vascular Endothelial Growth Factor. MMP, Matrix Metalloproteinase.
TIMP-1, Tissue inhibitor of metalloproteinases. ox LDL, oxidised low density lipoprotein.
Hb, Haemoglobin. sICAM-1, soluble intercellular adhesion molecule. hsCRP, high sensitivity C-reactive protein.
LTB4, Leukotriene B4. EDTA, Ethylenediaminetetraacetic acid.
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MLE to nicotine and tar will be estimated by a method
developed and published by the sponsor [23]. A portion
is cut from the mouth end of used cigarette filters col-
lected from all cigarettes smoked over a 24 h period.
The sponsor will provide the clinic with airtight collec-
tion tins for each participant, labelled with his or her
identification code, for use during each in-clinic evalu-
ation. Collected cigarette filters will be stored at room
temperature until dispatch to the sponsor for MLE ana-
lysis (usually within 1 week).
At the sponsor’s laboratories, the filter tips will be
placed in solvent and the extract will be analysed for
nicotine content and ultraviolet absorbance to show the
tar content. The data will be compared with calibration
curves, obtained from machine-smoking regimes where
smoke nicotine and tar yields are plotted against tip
nicotine and ultraviolet absorbance values; the slopes of
the curves represent the filtration efficiency of the
cigarette filter. These filtration efficiency data and the
amount of nicotine and tar retained on the cigarette fil-
ter will enable estimation of the amount of smoke that
exited the filter and entered the smokers’ mouths during
puffing (MLE).
Puffing, inhalation and exhalation measurements
Significant changes in smokers puffing and/or inhal-
ation/exhalation behaviour following the product switch
could affect the primary outcomes of this study.Therefore, puffing behaviour will be assessed in a normal
smoking environment with the devices Smoking Ana-
lyser version 7 (SA7) and breathe in/breathe out (BIBO)
apparatus, both of which have been designed, developed
and produced by the sponsor and are described else-
where [24]. The SA7 uses pressure transducers, built
into a hand-held cigarette holder, to measure puff flow,
volume and duration whilst the BIBO uses similar trans-
ducers in a second hand-held unit to measure inhal-
ation/exhalation parameters. Both devices connect to a
common-interface box and laptop computer where
puffing and inhalation/exhalation behaviour is recorded.
Two cigarettes will be smoked per measurement
through holders on the SA7 and BIBO apparatus. After
each puff, drawn through the SA7 holder, participants
will be asked to inhale and exhale up to five times
through the BIBO. They will wear nose clips during the
measurements but must try to puff, inhale and exhale as
normally as possible. This system provides a complete
record of the subject’s smoking behaviour, including puff
volume, puff duration, number of puffs, total puff vol-
ume, mouth-hold duration, depth and time of inhalation
and exhalation time.
Tests will be performed before and after switching for
smokers in the switching groups and at similar time
points for smokers in the non-switching groups. Owing
to this study design allowing smokers to smoke when
they wish, however, the specific timings of these mea-
surements cannot be scheduled a priori, but attempts
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each measurement day for individual participants. The
butts from the cigarettes smoked in these tests will be
pooled with the others collected for the subject that day
and sent to the sponsor for analysis.
Pulmonary function
Forced expiratory flow, forced expiratory flow in 1 s and
peak expiratory flow will be measured at screening and
once at the last in-clinic evaluation visit for every par-
ticipant. Additional measurements will be obtained once
in an in-clinic evaluation before switching and once dur-
ing an in-clinic evaluation after switching in the smoking
groups only.
Quality-of-life, sensory and diet and lifestyle assessments
Participants will be asked to self-administer study-
specific questionnaires, written in German, on a tablet
device during the in-clinic evaluation visits.
A prototype quality-of-life questionnaire, developed by
an independent expert and funded by the sponsor , will
be administered before switching and at the end of the
study in the smoking groups, and in the middle and at
the end of the study for the non-smoking groups. It will
capture multi-dimensional data on individuals’ subjective
perceptions on their daily lives, physical, psychological
and social functioning, and well-being.
A second questionnaire will be administered to smok-
ing groups before and multiple times after switching to
assess participants’ sensory impression of the products
and possibly assist in the interpretation of the toxicant
exposure and compliance data. Questions take into ac-
count standard sensory attributes associated with
cigarette smoking, including acceptability, draw effort,
amount of smoke, satisfaction, irritation, nicotine im-
pact, taste amount and quality, mouth dryness and after-
taste. Each attribute will be scored as magnitude and
liking.SMOKE
Days 1-14 (Baseline)
Supplied product  




7 mg ISO 
7 m
EX -SMOKERS AND N
Days 1-
No smo
(N = 60 each
Figure 2 Participant groups, group size and product switching.Aspects of an individual’s diet and lifestyle could affect
the biomarkers under investigation in this study. There-
fore, a third questionnaire will be administered to smok-
ing and non-smoking groups and aims to provide an
estimate of the participants’ normal standards of diet
and lifestyle.Statistical analysis
The sample size estimate is based on observed data for
BoE and BoBE and calculations made with MINITAB
software version 15 (two-sample t-test). Percentages of
reductions in smoke toxicants in the RTP versus com-
mercial products are assumed to translate into corre-
sponding reductions in BoE concentrations. Sample size
calculations were performed to achieve a power of 80%
to detect a difference between control and test products
at an alpha level of 0.05. On the basis of the least sensi-
tive BoE (aromatic amines), a sample size of 50 was de-
termined to be adequate for all BoE of interest in this
study (from study ISRCTN 72157335).
Similar estimates for BoBE are based on data for bio-
markers in urine and plasma previously obtained by the
sponsor and the least sensitive biomarkers in the litera-
ture, which showed that sample size of 50 would be ad-
equate for BoBE in the primary objective. Literature
search for secondary BoBE responses were uninforma-
tive, so sample size was assumed to be the same as for
the primary outcomes.
On the basis of these calculations and a 6-week study
in groups of 50 smokers (ISRCTN 72157335), it was es-
timated for this study that 70 participants per smoking
group will be required to allow for anticipated attrition
rates of up to 16% and achieve completion by at least 50
participants in each group. Sixty participants will be
recruited to each of the ex-smokers and never-smoker




tar yield commercial control cigarette
(N = 70)
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tailed statistical analysis plan will be prepared before data-
base closure and agreed by the sponsor and Celerion. Any
changes in the planned statistical methods will be docu-
mented in the study report.
The primary and secondary objectives will be exam-
ined by computing group biomarker levels at baseline,
midpoints and at the end of the study (Table 1). Data
for the primary outcome might be transformed to en-
sure that any assumptions associated with particular
statistical tests or models are obeyed. ANOVA will be
performed to identify differences between groups. As
cigarette consumption may change over time or as a re-
sult of the switch, an ANCOVA will also be performed,
using cigarettes per day as a covariate. For the second-
ary outcomes, an exploratory analysis with a matrix-
type approach, such as principle component analysis,
may be used.
A diagram summarising participant groups, group size
and product switching is shown as Figure 2
Discussion
A previous clinical study demonstrated that switching
smokers to prototype cigarettes with reduced levels of
certain toxicants in the smoke results in a reduction of
corresponding biomarkers of exposure [13]. This expos-
ure reduction cannot be extrapolated to a reduction in
risk. Therefore, this study has been designed to investi-
gate whether longer term use of such products leads to
continued exposure reduction and whether there is any
change in the levels of biomarkers of biological effect
(BoBE). Advantageous changes in BoBE may assist in a
“weight of evidence” assessment of the potential for
these products to reduce risk.
Data from this study are expected to increase scientific
understanding of combustible tobacco products with re-
duced toxicant yields and of how biomarkers may be
used to assess short-term and long-term effects in the
context of exposure and risk. The results will be pub-
lished in peer-reviewed scientific journals.
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